Showing results (251-260 of 261) with videos related to

Sort By:
Pageof 27
AIDS (London, England)|November 11, 2025
Health-related quality of life among people with HIV at low-to-moderate risk for atherosclerotic cardiovascular disease in the REPRIEVE TrialMarissa R Diggs, Sarah M Chu, Kathleen V Fitch, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 2, 2022
Factors Associated With Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People With Human Immunodeficiency Virus on Antiretroviral TherapySara E Looby, Amy Kantor, Tricia H Burdo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 26, 2025
Factors Affecting Risk of CVD Events in a Global CVD Prevention Cohort of People with HIVSteven K Grinspoon, Maya Watanabe, Heather J Ribaudo, et al.
JACC. Cardiovascular Imaging|December 1, 2025
Statin Effects on Pericoronary Adipose Tissue Density in People With HIV: Insights From the REPRIEVE TrialBorek Foldyna, Ibrahim Hadzic, Thomas Mayrhofer, et al.
JACC. Advances|June 28, 2024
Coronary Plaque in People With HIV vs Non-HIV Asymptomatic Community and Symptomatic Higher-Risk PopulationsJulia Karady, Michael T Lu, Göran Bergström, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 6, 2025
Clonal Hematopoiesis and Major Adverse Cardiac Events in People With HIV: Insights From the REPRIEVE TrialLiying Xue, Romit Bhattacharya, Md Mesbah Uddin, et al.
JAMA Cardiology|February 21, 2024
Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical TrialMichael T Lu, Heather Ribaudo, Borek Foldyna, et al.
The New England Journal of Medicine|July 24, 2023
Pitavastatin to Prevent Cardiovascular Disease in HIV InfectionSteven K Grinspoon, Kathleen V Fitch, Markella V Zanni, et al.
The Lancet. HIV|March 30, 2026
Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVEEmma M Kileel, Carlos D Malvestutto, Markella V Zanni, et al.
Open Forum Infectious Diseases|October 23, 2023
Biological and Clinical Implications of the Vascular Endothelial Growth Factor Coreceptor Neuropilin-1 in Human Immunodeficiency VirusSamuel R Schnittman, Márton Kolossváry, Gabriele Beck-Engeser, et al.
Pageof 27